Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-745-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees53
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions
What is Zosano Pharma's stock symbol?
Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Zosano Pharma shares reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Corp (NASDAQ:ZSAN) announced its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.16. View Zosano Pharma's Earnings History.
When is Zosano Pharma's next earnings date?
What price target have analysts set for ZSAN?
3 Wall Street analysts have issued 12-month price objectives for Zosano Pharma's shares. Their forecasts range from $3.66 to $19.00. On average, they expect Zosano Pharma's share price to reach $10.22 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price. View Analyst Price Targets for Zosano Pharma.
What is the consensus analysts' recommendation for Zosano Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.
Has Zosano Pharma been receiving favorable news coverage?
Media coverage about ZSAN stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zosano Pharma earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Protagonist Therapeutics (PTGX), resTORbio (TORC), Concert Pharmaceuticals (CNCE), Marinus Pharmaceuticals (MRNS), Syros Pharmaceuticals (SYRS), Ardelyx (ARDX), MEI Pharma (MEIP), Aeglea Bio Therapeutics (AGLE), Millendo Therapeutics (MLND), Spero Therapeutics (SPRO), Zynerba Pharmaceuticals (ZYNE), Osmotica Pharmaceuticals (OSMT), Poxel (PXXLF), Affimed (AFMD) and Galectin Therapeutics (GALT).
What other stocks do shareholders of Zosano Pharma own?
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the folowing people:
- Mr. John P. Walker, Chairman, CEO & Pres (Age 70)
- Ms. Hayley Lewis, Sr. VP of Operations (Age 43)
- Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 64)
- Mr. Greg Kitchener, Chief Financial Officer (Age 48)
- Jeffrey L. Quillen, Sec.
When did Zosano Pharma IPO?
(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
How do I buy shares of Zosano Pharma?
Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zosano Pharma's stock price today?
One share of ZSAN stock can currently be purchased for approximately $3.96.
How big of a company is Zosano Pharma?
Zosano Pharma has a market capitalization of $67.21 million. Zosano Pharma employs 53 workers across the globe.
What is Zosano Pharma's official website?
How can I contact Zosano Pharma?
Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]
MarketBeat Community Rating for Zosano Pharma (NASDAQ ZSAN)
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
